Small, flexible and modular in design, this technology can be fitted for LVAD, RVAD or pediatric treatments.
The Challenges of Treating Advance Heart Failure
Current therapies have proven inadequate in treating chronic heart failure.
Current Assist Devices
Market: The worldwide ventricular assist devices market, including left ventricular assist devices (LVAD), manufactures 10,000 pumps a year and is estimated at $1B.
Challenge: Overcoming AEs, including 9-14% annual stroke risk and the accompanying $150K re-hospitalization costs.
Market: An estimated 3,500 heart transplants are performed each year in the U.S.
Challenge: Shortage of donor hearts and complications due to anti-rejection therapy.
Market: The combination of multiple medications can benefit some heart failure patients.
Challenge: Combination therapies generally have limited efficacy, and patients ultimately become refractory to treatment. In addition, the widely-prescribed Entresto (Novartis) is indicated for HFrEF, not HFpEF patients.
Cardiac Resynchronization Therapy (CRT)
Market: CRT-D (defibrillation) and the CRT-P (pacemaker) devices have a current market value of $2B.
Challenge: Limited effectiveness over time, and minimal impact in 50% of patients.
Remodeling and Repair
Market: Parachute devices, patches, infarct exclusions and biopolymer gel are used to treat advanced heart failure.
Challenge: No clinical proof of efficacy.
Percutaneous catheter delivery eliminates challenging, open-chest heart surgery.
Reduces risk of adverse events such as stroke, bleeding, thrombosis and infection.
Lower Total Cost of Care
Lessens the total cost of care, from the device itself to the burden of re-hospitalization.
Industry pioneers lead the VADovations executive team.